Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562066 · ClinicalTrials.gov registry record · Phase 3
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
A Phase 3 study of Myasthenic Syndromes, Congenital, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT02562066 is a Phase 3 study of Myasthenic Syndromes, Congenital that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02562066, a Phase 3 study of Myasthenic Syndromes, Congenital, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG amifampridine phosphate
Study Locations (4)
California
- UCLA Department of Neurology - Los Angeles
Maryland
- Johns Hopkins Pediatric Neurology - Baltimore
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02562066
The ClinicalTrials.gov registry entry for NCT02562066 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenic Syndromes, Congenital appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02562066 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02562066 about?
NCT02562066 is a clinical study titled "Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes". This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphat...
What is the current status of trial NCT02562066?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2016-01. Estimated completion is 2019-10.
What conditions does trial NCT02562066 study?
This clinical trial studies the following conditions: Myasthenic Syndromes, Congenital.
What interventions are being tested in trial NCT02562066?
The interventions under investigation include: Placebo (DRUG), amifampridine phosphate (DRUG).
Who is sponsoring clinical trial NCT02562066?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02562066 being conducted?
This trial has 4 study locations across California, Maryland, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenic Syndromes, Congenital
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.